Home › Multiple Myeloma › Ohio › Cleveland
Pag-aaral pangklinika para sa Multiple Myeloma sa Cleveland, OH
14 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Cleveland (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Nagre-recruitPhase 3
- Cleveland Clinic, Cleveland
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Nagre-recruitPhase 2
- Cleveland Clinic, Cleveland
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 3
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Main Campus, Cleveland
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Cleveland Clinic, Cleveland
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Nagre-recruitObservasyonal na pag-aaral
- University Hospitals Seidman Cancer Center, Cleveland
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Nagre-recruitPhase 3
- Cleveland Clinic, Cleveland
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Nagre-recruitPhase 3
- Research Site, Cleveland
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Cleveland
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Nagre-recruitPhase 2
- University Hospitals Cleveland Medical Center, Cleveland
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Nagre-recruitPhase 3
- MetroHealth Medical Center, Cleveland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Cleveland
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Cleveland Clinic, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Nagre-recruitPhase 1/2
- University Hospitals Cleveland, Cleveland
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY59 pag-aaral
- Boston, MA45 pag-aaral
- Atlanta, GA42 pag-aaral
- Houston, TX39 pag-aaral
- Durham, NC36 pag-aaral
- Nashville, TN31 pag-aaral
- Denver, CO26 pag-aaral
- St. Louis, MO26 pag-aaral
- Rochester, MN25 pag-aaral
- Columbus, OH25 pag-aaral
- Chicago, IL24 pag-aaral
- Milwaukee, WI23 pag-aaral
Iba pang pag-aaral sa Cleveland
- Non-Small Cell Lung Cancer48 pag-aaral
- Kanser (lahat ng uri)36 pag-aaral
- Kanser sa Suso33 pag-aaral
- Pagkabigo ng Puso31 pag-aaral
- Metastatic Cancer30 pag-aaral
- Kanser sa Prostate30 pag-aaral
- Kanser sa Ovary29 pag-aaral
- Kanser sa Baga26 pag-aaral
- Colorectal Cancer25 pag-aaral
- Acute Myeloid Leukemia20 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg20 pag-aaral
- Sakit sa Puso at Ugat ng Dugo20 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.